Bibliographic Details
| Title: |
Association of mycophenolate and azathioprine use with cognitive function in systemic lupus. |
| Authors: |
Dobrowolski, Chrisanna, McGinley, John, Fazzari, Melissa, Su, Jiandong, Bingham, Kathleen S, Anderson, Nicole, Ruttan, Lesley, Beaton, Dorcas E, Wither, Joan E, Tartaglia, Maria Carmela, Kakvan, Mahta, Bonilla, Dennisse, Choi, May Y, Fritzler, Marvin J, Martinez, Juan Pablo Diaz, Katz, Patricia, Green, Robin, Putterman, Chaim, Touma, Zahi |
| Source: |
Rheumatology; May2023, Vol. 62 Issue 5, p1860-1869, 10p |
| Subject Terms: |
COGNITION disorders, AZATHIOPRINE, COMBINATION drug therapy, CONFIDENCE intervals, AGE distribution, MYCOPHENOLIC acid, SEX distribution, TREATMENT effectiveness, NEUROPROTECTIVE agents, RESEARCH funding, SYSTEMIC lupus erythematosus, LOGISTIC regression analysis, ODDS ratio, PHARMACODYNAMICS |
| Abstract: |
Objectives Cognitive dysfunction (CD) is a common manifestation of SLE that can have detrimental consequences for those affected. To date, no treatments have been approved for SLE-CD. This study aims to assess the association of azathioprine (AZA) and mycophenolate (MMF) use with SLE-CD, given that these medications have demonstrated neuroprotective qualities in prior studies. Methods Consecutive adult SLE patients presenting to a single healthcare center were considered for participation. The ACR neuropsychological battery for SLE was administered to consenting patients at 0, 6 and 12 months. Scores were compared with age- and sex-matched controls. Primary outcome was CD, defined as a z -score ≤−1.5 in two or more cognitive domains. Mixed-effects logistic regression models were constructed to estimate the odds of CD with respect to AZA and MMF use. Results A total of 300 participants representing 676 patient visits completed the study; 114 (38%) met criteria for CD at baseline. The cumulative AZA dose (g/kg) was associated with reduced odds of CD [odds ratio (OR) 0.76 (95% CI 0.58, 0.98), P = 0.04]. Years of AZA treatment was also associated with reduced odds of CD [OR 0.72 (95% CI 0.54, 0.97), P = 0.03]. MMF use was not associated with CD. Conclusion AZA use was associated with significantly lower odds of SLE-CD, while MMF use was not. Additional studies are warranted to further investigate the relationship of AZA and SLE-CD. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
